| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
D-Ala-ol is classified as a chiral amino alcohol and does not have a specific biological receptor target. Its primary application is as a chiral building block for the synthesis of pharmaceuticals, surfactants, and other chemicals. It is a core building block for the synthesis of ofloxacin and levofloxacin, which are essential drugs in China.
|
|---|---|
| ln Vitro |
For Coenzyme B(12) to function on both enantiomers of the substrate 2-amino-1-propanol, ethanolamine hydrolase is necessary.
In vitro activity for D-Ala-ol is primarily as a synthetic building block. Amino acid derivatives have been commercially used as ergogenic supplements. D-Ala-ol itself is not directly biologically active. Its utility is in preparing chiral compounds for pharmaceutical applications. As an amino alcohol, it can be converted into nonracemic adenine derivatives. |
| ln Vivo |
In vivo activity data for D-Ala-ol as a standalone compound is not applicable. It is a chiral building block used in pharmaceutical synthesis. Compounds synthesized using this building block may be evaluated in animal models. The compound itself is not a drug candidate for direct administration.
|
| Enzyme Assay |
In vitro protocols for D-Ala-ol are primarily synthetic. It is used as a chiral building block in pharmaceutical synthesis. The compound can be converted into various derivatives through standard organic chemistry reactions. Purity is typically ≥99% by GC. It appears as a colorless to light yellow viscous liquid. Storage is recommended in a refrigerator under inert gas.
|
| Cell Assay |
Cell-based protocols are not directly applicable to D-Ala-ol as it is a synthetic building block. Compounds synthesized using this reagent can be tested in cell culture. Compounds are dissolved in DMSO or appropriate buffers and added to cells at concentrations of 0.1-100 µM for 24-72 hours.
|
| Animal Protocol |
Animal studies with D-Ala-ol are not conducted directly. The compound may be used as a synthetic intermediate to prepare pharmaceuticals for in vivo evaluation. Standard synthetic chemistry protocols are used to convert this intermediate into target molecules for pharmaceutical research.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for D-Ala-ol as a standalone compound is not applicable. The compound has a molecular weight of 75.11 g/mol, formula C3H9NO, and CAS number 35320-23-1. It is very soluble in water and alcohols. Storage is recommended in a refrigerator under inert gas. It is a corrosive and combustible liquid.
|
| Toxicity/Toxicokinetics |
Limited toxicological data indicates D-Ala-ol causes severe skin burns and eye damage. The compound is for research use only. Standard safety precautions for handling corrosive liquids should be observed. It is not intended for human therapeutic use.
|
| Additional Infomation |
(R)-2-aminoprop-1-ol is a 2-aminoprop-1-ol with the R configuration. It is the enantiomer of (S)-2-aminoprop-1-ol.
D-Ala-ol (CAS#: 35320-23-1) is also known as D-Alaninol, (R)-(-)-2-Amino-1-propanol, and (R)-2-amino-1-propanol. It is a chiral amino alcohol used as a building block in pharmaceutical synthesis. It has no approved therapeutic indications. |
| Molecular Formula |
C3H9NO
|
|---|---|
| Molecular Weight |
75.1097
|
| Exact Mass |
75.068
|
| CAS # |
35320-23-1
|
| PubChem CID |
80308
|
| Appearance |
Colorless to light yellow Liquid
|
| Density |
0.9±0.1 g/cm3
|
| Boiling Point |
174.5±0.0 °C at 760 mmHg
|
| Melting Point |
8 °C
|
| Flash Point |
83.9±0.0 °C
|
| Vapour Pressure |
0.4±0.7 mmHg at 25°C
|
| Index of Refraction |
1.440
|
| LogP |
-0.96
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
5
|
| Complexity |
22.9
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O([H])C([H])([H])[C@@]([H])(C([H])([H])[H])N([H])[H]
|
| InChi Key |
BKMMTJMQCTUHRP-GSVOUGTGSA-N
|
| InChi Code |
InChI=1S/C3H9NO/c1-3(4)2-5/h3,5H,2,4H2,1H3/t3-/m1/s1
|
| Chemical Name |
(2R)-2-aminopropan-1-ol
|
| Synonyms |
D-Ala-ol; D-Alaninol
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 13.3138 mL | 66.5690 mL | 133.1381 mL | |
| 5 mM | 2.6628 mL | 13.3138 mL | 26.6276 mL | |
| 10 mM | 1.3314 mL | 6.6569 mL | 13.3138 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
